aibio
Listings ·
Ironwood Pharmaceuticals regains compliance with Nasdaq $1.00 bid price rule
Nasdaq told Ironwood on August 29, 2025 that the matter is closed. The company had received a deficiency notice on May 28, 2025.
IRWD Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals (IRWD) news IRWD Nasdaq notice news
Latest Ironwood Pharmaceuticals news
- Listings
Ironwood Pharmaceuticals gets Nasdaq minimum bid price deficiency notice
Nasdaq said Ironwood's Class A stock closed below $1.00 for 30 consecutive business days. The company has until November 24, 2025 to regain compliance, and the letter has no immediate effect on its listing.
- Listings
Ironwood Pharmaceuticals gets Nasdaq deficiency notice over late 2024 Form 10-K
Ironwood (Nasdaq: IRWD) has until May 20, 2025, to submit a plan to regain compliance with Nasdaq's timely filing rule and says it plans to file the 2024 Form 10-K as soon as practicable.
- Distress
Ironwood Pharmaceuticals delays 10-K and expects a material weakness finding
Ironwood said it expects its internal control over financial reporting to be ineffective as of December 31, 2024. It plans to file within the 15-day grace period.
What Ironwood Pharmaceuticals does
Ironwood Pharmaceuticals is a biotechnology company developing and commercializing therapies for gastrointestinal and rare diseases. Its commercial product, LINZESS (linaclotide), is the first product approved by the U.S. FDA in the class of guanylate cyclase type C agonists, and it is indicated in the U.S. for irritable bowel syndrome with constipation, chronic idiopathic constipation and pediatric functional constipation. Linaclotide is partnered with AbbVie for the U.S. and most markets worldwide, with AstraZeneca in China and with Astellas in Japan. Through its acquisition of VectivBio Holding AG in June 2023, Ironwood is advancing apraglutide, a long-acting GLP-2 analog for short bowel syndrome patients who are dependent on parenteral support. The pivotal Phase III STARS trial reported positive topline results in February 2024, but after discussions with the FDA, a confirmatory Phase III trial, STARS-2, is needed before a new drug application can be submitted. The company expects site initiations for STARS-2 to begin in the second quarter of 2026. Ironwood recognized $289.3 million in collaborative arrangements revenue from U.S. LINZESS sales in the year ended December 31, 2025, and generated $127.0 million in cash from operations, ending the year with $215.5 million in cash and cash equivalents.
| Product or program | What it is | Stage |
|---|---|---|
| LINZESS (linaclotide) | Guanylate cyclase type C agonist for IBS-C, chronic idiopathic constipation and pediatric functional constipation | Approved; commercial product |
| Apraglutide | Long-acting GLP-2 analog for short bowel syndrome patients dependent on parenteral support | Confirmatory Phase III (STARS-2) to be initiated |
Ironwood Pharmaceuticals annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $95.1 million | $111.4 million |
| Net income (loss) | $24.0 million | $880,000 |
| Cash from operations | $127.0 million | $103.5 million |
| Cash and equivalents | $215.5 million | $88.6 million |
Questions about Ironwood Pharmaceuticals
Has Ironwood Pharmaceuticals received a Nasdaq deficiency notice?
Our latest story on this, dated Sep 3, 2025: "Ironwood Pharmaceuticals regains compliance with Nasdaq $1.00 bid price rule". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Ironwood Pharmaceuticals?
Ironwood Pharmaceuticals, Inc. trades under the ticker IRWD on NASDAQ.
Where is Ironwood Pharmaceuticals listed?
Ironwood Pharmaceuticals, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:I76; LS:A0X789; LSX:A0X789.
What is the SEC CIK of Ironwood Pharmaceuticals?
The SEC Central Index Key (CIK) for Ironwood Pharmaceuticals, Inc. is 1446847. Its filings are on SEC EDGAR.
How many shares does Ironwood Pharmaceuticals have outstanding?
165,239,947 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-06.
Which country or territory is Ironwood Pharmaceuticals listed under?
Our directory records Ironwood Pharmaceuticals, Inc. under United States.
What does Ironwood Pharmaceuticals do?
Our directory classifies Ironwood Pharmaceuticals, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of Ironwood Pharmaceuticals?
The ISIN recorded for Ironwood Pharmaceuticals, Inc. is US46333X1081.
Does aibio.space cover Ironwood Pharmaceuticals?
aibio.space lists Ironwood Pharmaceuticals, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Ironwood Pharmaceuticals incorporated?
SEC records list its state or country of incorporation as DE.
What does Ironwood Pharmaceuticals develop?
Ironwood Pharmaceuticals is a biotechnology company developing and commercializing therapies for gastrointestinal and rare diseases. Its commercial product, LINZESS (linaclotide), is the first product approved by the U.S. FDA in the class of guanylate cyclase type C agonists, and it is indicated in the U.S. for irritable bowel syndrome with constipation, chronic idiopathic constipation and pediatric functional constipation.
What is LINZESS (linaclotide) from Ironwood Pharmaceuticals?
LINZESS (linaclotide): Guanylate cyclase type C agonist for IBS-C, chronic idiopathic constipation and pediatric functional constipation Stage: Approved; commercial product.
What is Apraglutide from Ironwood Pharmaceuticals?
Apraglutide: Long-acting GLP-2 analog for short bowel syndrome patients dependent on parenteral support Stage: Confirmatory Phase III (STARS-2) to be initiated.
Is Ironwood Pharmaceuticals profitable?
Ironwood Pharmaceuticals, Inc. reported net income of $24.0 million for the fiscal year ended Dec 31, 2025, and generated $127.0 million of cash from operations, per its annual report to the SEC.
How much does Ironwood Pharmaceuticals spend on research and development?
$95.1 million in the fiscal year ended Dec 31, 2025, per its annual report.
Investor discussion: Ironwood Pharmaceuticals
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Financings
Reported a financing. SEC Form 8-K (Items 8.01). Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
- Legal
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
- Distress
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 8.01,9.01). Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,7.01,9.01). Source
- Distress
Told the SEC a periodic report would be filed late. SEC Form NT 10-K. Source
- Distress
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05,5.02). Source
Stock chart
SEC filings and registration
- SEC name
- Ironwood Pharmaceuticals Inc
- CIK
- 1446847
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- US tickers
- IRWD (Nasdaq)
- State or country of incorporation
- DE
- Fiscal year ends
- December 31
- Filer category
- Accelerated filer<br>Smaller reporting company
- Business address
- 100 SUMMER STREET, SUITE 2300, BOSTON, MA, 02110
- Phone
- 617-621-7722
- Shares outstanding
- 165,239,947 as of 2026-07-31 (10-Q filed 2026-08-06)
Recent filings
Listing details
- Company
- Ironwood Pharmaceuticals, Inc.
- Ticker
- IRWD
- Listing
- NASDAQ
- Country or territory
- United States
- Business scope
- Pharmaceuticals: Major
- ISIN
- US46333X1081
- Other listed symbols
- GETTEX:I76; LS:A0X789; LSX:A0X789
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction